1	Induction	induction	NN	NN	_	0	root	_	_
2	of	of	IN	IN	_	4	case	_	_
3	cytokine	cytokine	NN	NN	_	4	compound	_	_
4	expression	expression	NN	NN	_	1	nmod	_	_
5	in	in	IN	IN	_	6	case	_	_
6	leukocytes	leukocyte	NNS	NNS	_	1	nmod	_	_
7	by	by	IN	IN	_	8	case	_	_
8	binding	binding	NN	NN	_	1	nmod	_	_
9	of	of	IN	IN	_	11	case	_	_
10	thrombin-stimulated	thrombin-stimulated	JJ	JJ	_	11	amod	_	_
11	platelets	platelet	NNS	NNS	_	8	nmod	_	_
12	.	.	.	.	_	1	punct	_	_

1	BACKGROUND	background	NN	NN	_	0	root	_	_
2	:	:	:	:	_	1	punct	_	_
3	Activated	activate	VBN	VBN	_	4	amod	_	_
4	platelets	platelet	NNS	NNS	_	5	nsubj	_	_
5	tether	tether	VBP	VBP	_	1	dep	_	_
6	and	and	CC	CC	_	5	cc	_	_
7	activate	activate	VBP	VBP	_	5	conj	_	_
8	myeloid	myeloid	JJ	JJ	_	9	amod	_	_
9	leukocytes	leukocyte	NNS	NNS	_	5	dobj	_	_
10	.	.	.	.	_	5	punct	_	_

1	To	to	TO	TO	_	2	mark	_	_
2	investigate	investigate	VB	VB	_	0	root	_	_
3	the	the	DT	DT	_	5	det	_	_
4	potential	potential	JJ	JJ	_	5	amod	_	_
5	relevance	relevance	NN	NN	_	2	dobj	_	_
6	of	of	IN	IN	_	8	case	_	_
7	this	this	DT	DT	_	8	det	_	_
8	mechanism	mechanism	NN	NN	_	5	nmod	_	_
9	in	in	IN	IN	_	12	case	_	_
10	acute	acute	JJ	JJ	_	12	amod	_	_
11	myocardial	myocardial	JJ	JJ	_	12	amod	_	_
12	infarction	infarction	NN	NN	_	5	nmod	_	_
13	(	(	-LRB-	-LRB-	_	14	punct	_	_
14	AMI	ami	NN	NN	_	12	appos	_	_
15	)	)	-RRB-	-RRB-	_	14	punct	_	_
16	,	,	,	,	_	2	punct	_	_
17	we	we	PRP	PRP	_	18	nsubj	_	_
18	examined	examine	VBD	VBD	_	2	parataxis	_	_
19	cytokine	cytokine	NN	NN	_	20	compound	_	_
20	induction	induction	NN	NN	_	18	dobj	_	_
21	by	by	IN	IN	_	23	case	_	_
22	leukocyte-platelet	leukocyte-platelet	JJ	JJ	_	23	amod	_	_
23	adhesion	adhesion	NN	NN	_	20	nmod	_	_
24	and	and	CC	CC	_	20	cc	_	_
25	the	the	DT	DT	_	26	det	_	_
26	occurrence	occurrence	NN	NN	_	20	conj	_	_
27	of	of	IN	IN	_	29	case	_	_
28	leukocyte-platelet	leukocyte-platelet	JJ	JJ	_	29	amod	_	_
29	conjugates	conjugate	NNS	NNS	_	26	nmod	_	_
30	in	in	IN	IN	_	31	case	_	_
31	patients	patient	NNS	NNS	_	18	nmod	_	_
32	with	with	IN	IN	_	33	case	_	_
33	AMI	ami	NN	NN	_	31	nmod	_	_
34	.	.	.	.	_	2	punct	_	_

1	METHODS	method	NNS	NNS	_	0	root	_	_
2	AND	and	CC	CC	_	1	cc	_	_
3	RESULTS	result	NNS	NNS	_	1	conj	_	_
4	:	:	:	:	_	1	punct	_	_
5	We	we	PRP	PRP	_	1	dep	_	_
6	obtained	obtain	VBD	VBD	_	1	acl	_	_
7	peripheral	peripheral	JJ	JJ	_	10	amod	_	_
8	venous	venous	JJ	JJ	_	10	amod	_	_
9	blood	blood	NN	NN	_	10	compound	_	_
10	samples	sample	NNS	NNS	_	6	dobj	_	_
11	in	in	IN	IN	_	13	case	_	_
12	20	20	CD	CD	_	13	nummod	_	_
13	patients	patient	NNS	NNS	_	6	nmod	_	_
14	with	with	IN	IN	_	15	case	_	_
15	AMI	ami	NN	NN	_	13	nmod	_	_
16	before	before	IN	IN	_	13	nmod	_	_
17	and	and	CC	CC	_	16	cc	_	_
18	daily	daily	RB	RB	_	21	advmod	_	_
19	for	for	IN	IN	_	21	case	_	_
20	5	5	CD	CD	_	21	nummod	_	_
21	days	day	NNS	NNS	_	16	conj	_	_
22	after	after	IN	IN	_	27	case	_	_
23	direct	direct	JJ	JJ	_	27	amod	_	_
24	percutaneous	percutaneous	JJ	JJ	_	27	amod	_	_
25	transluminal	transluminal	JJ	JJ	_	27	amod	_	_
26	coronary	coronary	JJ	JJ	_	27	amod	_	_
27	angioplasty	angioplasty	NN	NN	_	21	nmod	_	_
28	(	(	-LRB-	-LRB-	_	29	punct	_	_
29	PTCA	ptca	NN	NN	_	27	appos	_	_
30	)	)	-RRB-	-RRB-	_	29	punct	_	_
31	and	and	CC	CC	_	13	cc	_	_
32	in	in	IN	IN	_	34	case	_	_
33	20	20	CD	CD	_	34	nummod	_	_
34	patients	patient	NNS	NNS	_	13	conj	_	_
35	undergoing	undergo	VBG	VBG	_	34	acl	_	_
36	elective	elective	JJ	JJ	_	37	amod	_	_
37	PTCA	ptca	NN	NN	_	35	dobj	_	_
38	.	.	.	.	_	1	punct	_	_

1	Throughout	throughout	IN	IN	_	4	case	_	_
2	the	the	DT	DT	_	4	det	_	_
3	study	study	NN	NN	_	4	compound	_	_
4	period	period	NN	NN	_	14	nmod	_	_
5	,	,	,	,	_	14	punct	_	_
6	CD41	cd41	NN	NN	_	7	compound	_	_
7	immunofluorescence	immunofluorescence	NN	NN	_	14	nsubj	_	_
8	of	of	IN	IN	_	9	case	_	_
9	leukocytes	leukocyte	NNS	NNS	_	7	nmod	_	_
10	(	(	-LRB-	-LRB-	_	12	punct	_	_
11	flow	flow	NN	NN	_	12	compound	_	_
12	cytometry	cytometry	NN	NN	_	7	appos	_	_
13	)	)	-RRB-	-RRB-	_	12	punct	_	_
14	revealed	reveal	VBD	VBD	_	0	root	_	_
15	increased	increase	VBN	VBN	_	17	amod	_	_
16	leukocyte-platelet	leukocyte-platelet	JJ	JJ	_	17	amod	_	_
17	adhesion	adhesion	NN	NN	_	14	dobj	_	_
18	in	in	IN	IN	_	19	case	_	_
19	patients	patient	NNS	NNS	_	17	nmod	_	_
20	with	with	IN	IN	_	21	case	_	_
21	AMI	ami	NN	NN	_	19	nmod	_	_
22	compared	compare	VBN	VBN	_	25	case	_	_
23	with	with	IN	IN	_	25	case	_	_
24	control	control	JJ	JJ	_	25	amod	_	_
25	patients	patient	NNS	NNS	_	17	nmod	_	_
26	(	(	-LRB-	-LRB-	_	27	punct	_	_
27	mean	mean	NN	NN	_	25	dep	_	_
28	+/-	+/-	CC	CC	_	27	cc	_	_
29	SE	se	NN	NN	_	27	conj	_	_
30	of	of	IN	IN	_	31	case	_	_
31	fluorescence	fluorescence	NN	NN	_	27	nmod	_	_
32	-LSB-	-lsb-	-LRB-	-LRB-	_	33	punct	_	_
33	channels	channel	NNS	NNS	_	27	appos	_	_
34	-RSB-	-rsb-	-RRB-	-RRB-	_	33	punct	_	_
35	before	before	IN	IN	_	36	case	_	_
36	PTCA	ptca	NN	NN	_	27	nmod	_	_
37	:	:	:	:	_	27	punct	_	_
38	77	77	CD	CD	_	27	dep	_	_
39	+/-	+/-	CC	CC	_	38	cc	_	_
40	16	16	CD	CD	_	38	conj	_	_
41	versus	versus	CC	CC	_	38	cc	_	_
42	35	35	CD	CD	_	38	conj	_	_
43	+/-	+/-	CC	CC	_	42	cc	_	_
44	9	9	CD	CD	_	42	conj	_	_
45	;	;	:	:	_	27	punct	_	_
46	P	p	NN	NN	_	27	dep	_	_
47	=	=	JJ	JJ	_	46	amod	_	_
48	.003	.003	CD	CD	_	47	dep	_	_
49	)	)	-RRB-	-RRB-	_	27	punct	_	_
50	.	.	.	.	_	14	punct	_	_

1	In	in	FW	FW	_	2	compound	_	_
2	vitro	vitro	FW	FW	_	7	advmod	_	_
3	,	,	,	,	_	7	punct	_	_
4	thrombin-stimulated	thrombin-stimulated	JJ	JJ	_	6	amod	_	_
5	fixed	fixed	JJ	JJ	_	6	amod	_	_
6	platelets	platelet	NNS	NNS	_	7	nsubj	_	_
7	bound	bind	VBD	VBD	_	0	root	_	_
8	to	to	TO	TO	_	9	case	_	_
9	neutrophils	neutrophil	NNS	NNS	_	7	nmod	_	_
10	and	and	CC	CC	_	9	cc	_	_
11	monocytes	monocyte	NNS	NNS	_	9	conj	_	_
12	.	.	.	.	_	7	punct	_	_

1	Within	within	IN	IN	_	3	case	_	_
2	2	2	CD	CD	_	3	nummod	_	_
3	hours	hour	NNS	NNS	_	6	nmod	_	_
4	,	,	,	,	_	6	punct	_	_
5	this	this	DT	DT	_	6	nsubj	_	_
6	resulted	result	VBD	VBD	_	0	root	_	_
7	in	in	IN	IN	_	9	case	_	_
8	increased	increase	VBN	VBN	_	9	amod	_	_
9	mRNA	mrna	NN	NN	_	6	nmod	_	_
10	for	for	IN	IN	_	17	case	_	_
11	interleukin	interleukin	NN	NN	_	17	compound	_	_
12	(	(	-LRB-	-LRB-	_	17	punct	_	_
13	IL	il	NN	NN	_	17	compound	_	_
14	)	)	-RRB-	-RRB-	_	17	punct	_	_
15	,	,	,	,	_	17	punct	_	_
16	1	1	CD	CD	_	17	nummod	_	_
17	beta	beta	NN	NN	_	9	nmod	_	_
18	,	,	,	,	_	17	punct	_	_
19	IL-8	il-8	NN	NN	_	17	conj	_	_
20	,	,	,	,	_	17	punct	_	_
21	and	and	CC	CC	_	17	cc	_	_
22	monocyte	monocyte	NN	NN	_	26	compound	_	_
23	chemoattractant	chemoattractant	NN	NN	_	26	compound	_	_
24	protein	protein	NN	NN	_	26	compound	_	_
25	(	(	-LRB-	-LRB-	_	26	punct	_	_
26	MCP	mcp	NN	NN	_	17	conj	_	_
27	)	)	-RRB-	-RRB-	_	26	punct	_	_
28	-1	-1	CD	CD	_	26	nummod	_	_
29	in	in	IN	IN	_	31	case	_	_
30	unfractionated	unfractionated	JJ	JJ	_	31	amod	_	_
31	leukocytes	leukocyte	NNS	NNS	_	9	nmod	_	_
32	.	.	.	.	_	6	punct	_	_

1	After	after	IN	IN	_	3	case	_	_
2	4	4	CD	CD	_	3	nummod	_	_
3	hours	hour	NNS	NNS	_	15	nmod	_	_
4	,	,	,	,	_	15	punct	_	_
5	IL-1	il-1	NN	NN	_	6	compound	_	_
6	beta	beta	NN	NN	_	15	nsubj	_	_
7	and	and	CC	CC	_	6	cc	_	_
8	IL-8	il-8	NN	NN	_	6	conj	_	_
9	concentration	concentration	NN	NN	_	6	dep	_	_
10	of	of	IN	IN	_	13	case	_	_
11	the	the	DT	DT	_	13	det	_	_
12	cell-free	cell-free	JJ	JJ	_	13	amod	_	_
13	supernatant	supernatant	NN	NN	_	6	nmod	_	_
14	had	have	VBD	VBD	_	15	aux	_	_
15	increased	increase	VBN	VBN	_	0	root	_	_
16	by	by	IN	IN	_	20	case	_	_
17	268	268	CD	CD	_	20	nummod	_	_
18	+/-	+/-	CC	CC	_	17	cc	_	_
19	36	36	CD	CD	_	17	conj	_	_
20	%	%	NN	NN	_	15	nmod	_	_
21	and	and	CC	CC	_	20	cc	_	_
22	210	210	CD	CD	_	25	nummod	_	_
23	+/-	+/-	CC	CC	_	22	cc	_	_
24	7	7	CD	CD	_	22	conj	_	_
25	%	%	NN	NN	_	20	conj	_	_
26	,	,	,	,	_	15	punct	_	_
27	respectively	respectively	RB	RB	_	15	advmod	_	_
28	,	,	,	,	_	15	punct	_	_
29	and	and	CC	CC	_	15	cc	_	_
30	cellular	cellular	JJ	JJ	_	32	amod	_	_
31	MCP-1	mcp-1	NN	NN	_	32	compound	_	_
32	content	content	NN	NN	_	34	nsubj	_	_
33	had	have	VBD	VBD	_	34	aux	_	_
34	increased	increase	VBN	VBN	_	15	conj	_	_
35	by	by	IN	IN	_	39	case	_	_
36	170	170	CD	CD	_	39	nummod	_	_
37	+/-	+/-	CC	CC	_	36	cc	_	_
38	8	8	CD	CD	_	36	conj	_	_
39	%	%	NN	NN	_	34	nmod	_	_
40	.	.	.	.	_	15	punct	_	_

1	Addition	addition	NN	NN	_	8	nsubj	_	_
2	of	of	IN	IN	_	4	case	_	_
3	activated	activate	VBN	VBN	_	4	amod	_	_
4	platelets	platelet	NNS	NNS	_	1	nmod	_	_
5	to	to	TO	TO	_	7	case	_	_
6	adherent	adherent	JJ	JJ	_	7	amod	_	_
7	monocytes	monocyte	NNS	NNS	_	1	nmod	_	_
8	had	have	VBD	VBD	_	0	root	_	_
9	a	a	DT	DT	_	11	det	_	_
10	similar	similar	JJ	JJ	_	11	amod	_	_
11	effect	effect	NN	NN	_	8	dobj	_	_
12	and	and	CC	CC	_	8	cc	_	_
13	was	be	VBD	VBD	_	14	auxpass	_	_
14	associated	associate	VBN	VBN	_	8	conj	_	_
15	with	with	IN	IN	_	19	case	_	_
16	nuclear	nuclear	JJ	JJ	_	18	amod	_	_
17	factor-kappa	factor-kappa	NN	NN	_	18	compound	_	_
18	B	b	NN	NN	_	19	compound	_	_
19	activation	activation	NN	NN	_	14	nmod	_	_
20	.	.	.	.	_	8	punct	_	_

1	Inhibition	inhibition	NN	NN	_	8	nsubj	_	_
2	of	of	IN	IN	_	3	case	_	_
3	binding	binding	NN	NN	_	1	nmod	_	_
4	by	by	IN	IN	_	7	case	_	_
5	anti-P	anti-p	JJ	JJ	_	7	amod	_	_
6	selectin	selectin	NN	NN	_	7	compound	_	_
7	antibodies	antibody	NNS	NNS	_	1	nmod	_	_
8	reduced	reduce	VBD	VBD	_	0	root	_	_
9	the	the	DT	DT	_	10	det	_	_
10	effect	effect	NN	NN	_	8	dobj	_	_
11	of	of	IN	IN	_	13	case	_	_
12	activated	activate	VBN	VBN	_	13	amod	_	_
13	platelets	platelet	NNS	NNS	_	10	nmod	_	_
14	on	on	IN	IN	_	16	case	_	_
15	cytokine	cytokine	NN	NN	_	16	compound	_	_
16	production	production	NN	NN	_	10	nmod	_	_
17	.	.	.	.	_	8	punct	_	_

1	CONCLUSIONS	conclusion	NNS	NNS	_	0	root	_	_
2	:	:	:	:	_	1	punct	_	_
3	In	in	IN	IN	_	4	case	_	_
4	patients	patient	NNS	NNS	_	11	nmod	_	_
5	with	with	IN	IN	_	6	case	_	_
6	AMI	ami	NN	NN	_	4	nmod	_	_
7	,	,	,	,	_	11	punct	_	_
8	leukocyte-platelet	leukocyte-platelet	JJ	JJ	_	9	amod	_	_
9	adhesion	adhesion	NN	NN	_	11	nsubjpass	_	_
10	is	be	VBZ	VBZ	_	11	auxpass	_	_
11	increased	increase	VBN	VBN	_	1	dep	_	_
12	.	.	.	.	_	1	punct	_	_

1	Binding	binding	NN	NN	_	5	nsubj	_	_
2	of	of	IN	IN	_	4	case	_	_
3	activated	activate	VBN	VBN	_	4	amod	_	_
4	platelets	platelet	NNS	NNS	_	1	nmod	_	_
5	induces	induce	VBZ	VBZ	_	0	root	_	_
6	IL-1	il-1	NN	NN	_	7	compound	_	_
7	beta	beta	NN	NN	_	5	dobj	_	_
8	,	,	,	,	_	7	punct	_	_
9	IL-8	il-8	NN	NN	_	7	conj	_	_
10	,	,	,	,	_	7	punct	_	_
11	and	and	CC	CC	_	7	cc	_	_
12	MCP-1	mcp-1	NN	NN	_	7	conj	_	_
13	in	in	IN	IN	_	14	case	_	_
14	leukocytes	leukocyte	NNS	NNS	_	5	nmod	_	_
15	.	.	.	.	_	5	punct	_	_

1	Our	we	PRP$	PRP$	_	2	nmod:poss	_	_
2	findings	finding	NNS	NNS	_	3	nsubj	_	_
3	suggest	suggest	VBP	VBP	_	0	root	_	_
4	that	that	IN	IN	_	7	mark	_	_
5	leukocyte-platelet	leukocyte-platelet	JJ	JJ	_	6	amod	_	_
6	adhesion	adhesion	NN	NN	_	7	nsubj	_	_
7	contributes	contribute	VBZ	VBZ	_	3	ccomp	_	_
8	to	to	TO	TO	_	10	case	_	_
9	the	the	DT	DT	_	10	det	_	_
10	regulation	regulation	NN	NN	_	7	nmod	_	_
11	of	of	IN	IN	_	13	case	_	_
12	inflammatory	inflammatory	JJ	JJ	_	13	amod	_	_
13	responses	response	NNS	NNS	_	10	nmod	_	_
14	in	in	IN	IN	_	15	case	_	_
15	AMI	ami	NN	NN	_	10	nmod	_	_
16	.	.	.	.	_	3	punct	_	_

1	Defective	defective	JJ	JJ	_	2	amod	_	_
2	survival	survival	NN	NN	_	0	root	_	_
3	and	and	CC	CC	_	2	cc	_	_
4	activation	activation	NN	NN	_	2	conj	_	_
5	of	of	IN	IN	_	6	case	_	_
6	thymocytes	thymocyte	NNS	NNS	_	2	nmod	_	_
7	in	in	IN	IN	_	9	case	_	_
8	transgenic	transgenic	JJ	JJ	_	9	amod	_	_
9	mice	mouse	NNS	NNS	_	2	nmod	_	_
10	expressing	express	VBG	VBG	_	9	acl	_	_
11	a	a	DT	DT	_	14	det	_	_
12	catalytically	catalytically	RB	RB	_	14	advmod	_	_
13	inactive	inactive	JJ	JJ	_	14	amod	_	_
14	form	form	NN	NN	_	10	dobj	_	_
15	of	of	IN	IN	_	18	case	_	_
16	Ca2+/calmodulin-dependent	ca2+/calmodulin-dependent	JJ	JJ	_	18	amod	_	_
17	protein	protein	NN	NN	_	18	compound	_	_
18	kinase	kinase	NN	NN	_	14	nmod	_	_
19	IV	iv	CD	CD	_	18	nummod	_	_
20	.	.	.	.	_	2	punct	_	_

1	We	we	PRP	PRP	_	3	nsubj	_	_
2	have	have	VBP	VBP	_	3	aux	_	_
3	generated	generate	VBN	VBN	_	0	root	_	_
4	transgenic	transgenic	JJ	JJ	_	5	amod	_	_
5	mice	mouse	NNS	NNS	_	3	dobj	_	_
6	that	that	WDT	WDT	_	7	nsubj	_	_
7	express	express	VBP	VBP	_	5	acl:relcl	_	_
8	a	a	DT	DT	_	11	det	_	_
9	catalytically	catalytically	RB	RB	_	11	advmod	_	_
10	inactive	inactive	JJ	JJ	_	11	amod	_	_
11	form	form	NN	NN	_	7	dobj	_	_
12	of	of	IN	IN	_	15	case	_	_
13	Ca2+/calmodulin-dependent	ca2+/calmodulin-dependent	JJ	JJ	_	15	amod	_	_
14	protein	protein	NN	NN	_	15	compound	_	_
15	kinase	kinase	NN	NN	_	11	nmod	_	_
16	IV	iv	CD	CD	_	15	nummod	_	_
17	(	(	-LRB-	-LRB-	_	18	punct	_	_
18	CaMKIV	camkiv	NN	NN	_	15	appos	_	_
19	)	)	-RRB-	-RRB-	_	18	punct	_	_
20	specifically	specifically	RB	RB	_	24	advmod	_	_
21	in	in	IN	IN	_	24	case	_	_
22	thymic	thymic	JJ	JJ	_	24	amod	_	_
23	T	t	NN	NN	_	24	compound	_	_
24	cells	cell	NNS	NNS	_	7	nmod	_	_
25	.	.	.	.	_	3	punct	_	_

1	The	the	DT	DT	_	2	det	_	_
2	presence	presence	NN	NN	_	6	nsubj	_	_
3	of	of	IN	IN	_	5	case	_	_
4	this	this	DT	DT	_	5	det	_	_
5	protein	protein	NN	NN	_	2	nmod	_	_
6	results	result	VBZ	VBZ	_	0	root	_	_
7	in	in	IN	IN	_	12	case	_	_
8	a	a	DT	DT	_	12	det	_	_
9	markedly	markedly	RB	RB	_	10	advmod	_	_
10	reduced	reduce	VBN	VBN	_	12	amod	_	_
11	thymic	thymic	JJ	JJ	_	12	amod	_	_
12	cellularity	cellularity	NN	NN	_	6	nmod	_	_
13	,	,	,	,	_	6	punct	_	_
14	although	although	IN	IN	_	22	mark	_	_
15	the	the	DT	DT	_	16	det	_	_
16	distribution	distribution	NN	NN	_	22	nsubj	_	_
17	of	of	IN	IN	_	20	case	_	_
18	the	the	DT	DT	_	20	det	_	_
19	remaining	remain	VBG	VBG	_	20	amod	_	_
20	cells	cell	NNS	NNS	_	16	nmod	_	_
21	is	be	VBZ	VBZ	_	22	cop	_	_
22	normal	normal	JJ	JJ	_	6	advcl	_	_
23	based	base	VBN	VBN	_	25	case	_	_
24	on	on	IN	IN	_	25	case	_	_
25	evaluation	evaluation	NN	NN	_	22	advcl	_	_
26	of	of	IN	IN	_	28	case	_	_
27	the	the	DT	DT	_	28	dep	_	_
28	CD4	cd4	NN	NN	_	25	nmod	_	_
29	and	and	CC	CC	_	28	cc	_	_
30	CD8	cd8	NN	NN	_	28	conj	_	_
31	cell	cell	NN	NN	_	33	compound	_	_
32	surface	surface	NN	NN	_	33	compound	_	_
33	antigens	antigen	NNS	NNS	_	28	dep	_	_
34	that	that	WDT	WDT	_	36	nsubjpass	_	_
35	are	be	VBP	VBP	_	36	auxpass	_	_
36	used	use	VBN	VBN	_	28	acl:relcl	_	_
37	to	to	TO	TO	_	38	mark	_	_
38	gauge	gauge	VB	VB	_	36	xcomp	_	_
39	T	t	NN	NN	_	41	compound	_	_
40	cell	cell	NN	NN	_	41	compound	_	_
41	development	development	NN	NN	_	38	dobj	_	_
42	.	.	.	.	_	6	punct	_	_

1	Isolated	isolate	VBN	VBN	_	4	amod	_	_
2	thymic	thymic	JJ	JJ	_	4	amod	_	_
3	T	t	NN	NN	_	4	compound	_	_
4	cells	cell	NNS	NNS	_	10	nsubj	_	_
5	from	from	IN	IN	_	8	case	_	_
6	the	the	DT	DT	_	8	det	_	_
7	transgenic	transgenic	JJ	JJ	_	8	amod	_	_
8	mice	mouse	NNS	NNS	_	4	nmod	_	_
9	also	also	RB	RB	_	10	advmod	_	_
10	show	show	VBP	VBP	_	0	root	_	_
11	a	a	DT	DT	_	15	det	_	_
12	dramatically	dramatically	RB	RB	_	13	advmod	_	_
13	decreased	decrease	VBN	VBN	_	15	amod	_	_
14	survival	survival	NN	NN	_	15	compound	_	_
15	rate	rate	NN	NN	_	10	dobj	_	_
16	when	when	WRB	WRB	_	17	advmod	_	_
17	evaluated	evaluate	VBN	VBN	_	10	advcl	_	_
18	in	in	IN	IN	_	19	case	_	_
19	culture	culture	NN	NN	_	17	nmod	_	_
20	under	under	IN	IN	_	21	case	_	_
21	conditions	condition	NNS	NNS	_	19	nmod	_	_
22	that	that	WDT	WDT	_	25	nsubj	_	_
23	do	do	VBP	VBP	_	25	aux	_	_
24	not	not	RB	RB	_	25	neg	_	_
25	favor	favor	VB	VB	_	21	acl:relcl	_	_
26	activation	activation	NN	NN	_	25	dobj	_	_
27	.	.	.	.	_	10	punct	_	_

1	When	when	WRB	WRB	_	2	advmod	_	_
2	challenged	challenge	VBN	VBN	_	23	advcl	_	_
3	with	with	IN	IN	_	6	case	_	_
4	an	a	DT	DT	_	6	det	_	_
5	activating	activate	VBG	VBG	_	6	amod	_	_
6	stimulus	stimulus	NN	NN	_	2	nmod	_	_
7	such	such	JJ	JJ	_	9	case	_	_
8	as	as	IN	IN	_	7	mwe	_	_
9	alpha-CD3	alpha-cd3	NN	NN	_	6	nmod	_	_
10	or	or	CC	CC	_	9	cc	_	_
11	a	a	DT	DT	_	12	det	_	_
12	combination	combination	NN	NN	_	9	conj	_	_
13	of	of	IN	IN	_	15	case	_	_
14	phorbol	phorbol	NN	NN	_	15	compound	_	_
15	ester	ester	NN	NN	_	12	nmod	_	_
16	plus	plus	CC	CC	_	15	cc	_	_
17	ionophore	ionophore	NN	NN	_	15	conj	_	_
18	,	,	,	,	_	23	punct	_	_
19	the	the	DT	DT	_	20	det	_	_
20	cells	cell	NNS	NNS	_	23	nsubjpass	_	_
21	are	be	VBP	VBP	_	23	auxpass	_	_
22	severely	severely	RB	RB	_	23	advmod	_	_
23	compromised	compromise	VBN	VBN	_	0	root	_	_
24	in	in	IN	IN	_	26	case	_	_
25	their	they	PRP$	PRP$	_	26	nmod:poss	_	_
26	ability	ability	NN	NN	_	23	nmod	_	_
27	to	to	TO	TO	_	28	mark	_	_
28	produce	produce	VB	VB	_	26	acl	_	_
29	the	the	DT	DT	_	30	det	_	_
30	cytokine	cytokine	NN	NN	_	28	dobj	_	_
31	interleukin-2	interleukin-2	NN	NN	_	30	dep	_	_
32	(	(	-LRB-	-LRB-	_	33	punct	_	_
33	IL-2	il-2	NN	NN	_	31	appos	_	_
34	)	)	-RRB-	-RRB-	_	33	punct	_	_
35	.	.	.	.	_	23	punct	_	_

1	Reduction	reduction	NN	NN	_	6	nsubj	_	_
2	of	of	IN	IN	_	4	case	_	_
3	IL-2	il-2	NN	NN	_	4	compound	_	_
4	production	production	NN	NN	_	1	nmod	_	_
5	is	be	VBZ	VBZ	_	6	cop	_	_
6	secondary	secondary	JJ	JJ	_	0	root	_	_
7	to	to	TO	TO	_	9	case	_	_
8	the	the	DT	DT	_	9	det	_	_
9	inability	inability	NN	NN	_	6	nmod	_	_
10	to	to	TO	TO	_	11	mark	_	_
11	phosphorylate	phosphorylate	VB	VB	_	9	acl	_	_
12	the	the	DT	DT	_	17	det	_	_
13	cAMP	camp	NN	NN	_	17	compound	_	_
14	response	response	NN	NN	_	17	compound	_	_
15	element	element	NN	NN	_	17	compound	_	_
16	binding	binding	NN	NN	_	17	compound	_	_
17	protein	protein	NN	NN	_	11	dobj	_	_
18	,	,	,	,	_	17	punct	_	_
19	CREB	creb	NN	NN	_	17	appos	_	_
20	,	,	,	,	_	11	punct	_	_
21	and	and	CC	CC	_	11	cc	_	_
22	induce	induce	VBP	VBP	_	11	conj	_	_
23	expression	expression	NN	NN	_	22	dobj	_	_
24	of	of	IN	IN	_	28	case	_	_
25	the	the	DT	DT	_	28	det	_	_
26	immediate	immediate	JJ	JJ	_	28	amod	_	_
27	early	early	JJ	JJ	_	28	amod	_	_
28	genes	gene	NNS	NNS	_	23	nmod	_	_
29	such	such	JJ	JJ	_	32	case	_	_
30	as	as	IN	IN	_	29	mwe	_	_
31	Fos	fos	NN	NN	_	32	compound	_	_
32	B	b	NN	NN	_	28	nmod	_	_
33	that	that	WDT	WDT	_	35	nsubjpass	_	_
34	are	be	VBP	VBP	_	35	auxpass	_	_
35	required	require	VBN	VBN	_	28	acl:relcl	_	_
36	to	to	TO	TO	_	37	mark	_	_
37	transactivate	transactivate	VB	VB	_	35	xcomp	_	_
38	the	the	DT	DT	_	40	det	_	_
39	IL-2	il-2	NN	NN	_	40	compound	_	_
40	promoter	promoter	NN	NN	_	37	dobj	_	_
41	.	.	.	.	_	6	punct	_	_

1	Because	because	IN	IN	_	5	mark	_	_
2	transgene	transgene	NN	NN	_	3	compound	_	_
3	expression	expression	NN	NN	_	5	nsubjpass	_	_
4	was	be	VBD	VBD	_	5	auxpass	_	_
5	regulated	regulate	VBN	VBN	_	33	advcl	_	_
6	by	by	IN	IN	_	9	case	_	_
7	the	the	DT	DT	_	9	det	_	_
8	proximal	proximal	JJ	JJ	_	9	amod	_	_
9	promoter	promoter	NN	NN	_	5	nmod	_	_
10	of	of	IN	IN	_	14	case	_	_
11	the	the	DT	DT	_	14	det	_	_
12	murine	murine	JJ	JJ	_	14	amod	_	_
13	lck	lck	NN	NN	_	14	compound	_	_
14	gene	gene	NN	NN	_	9	nmod	_	_
15	and	and	CC	CC	_	5	cc	_	_
16	this	this	DT	DT	_	17	det	_	_
17	promoter	promoter	NN	NN	_	19	nsubjpass	_	_
18	is	be	VBZ	VBZ	_	19	auxpass	_	_
19	inactivated	inactivate	VBN	VBN	_	5	conj	_	_
20	in	in	IN	IN	_	22	case	_	_
21	T	t	NN	NN	_	22	compound	_	_
22	cells	cell	NNS	NNS	_	19	nmod	_	_
23	that	that	WDT	WDT	_	24	nsubj	_	_
24	exit	exit	VBP	VBP	_	22	acl:relcl	_	_
25	the	the	DT	DT	_	26	det	_	_
26	thymus	thymus	NN	NN	_	24	dobj	_	_
27	,	,	,	,	_	33	punct	_	_
28	the	the	DT	DT	_	30	det	_	_
29	mutant	mutant	JJ	JJ	_	30	amod	_	_
30	hCaMKIV	hcamkiv	NN	NN	_	33	nsubj	_	_
31	is	be	VBZ	VBZ	_	33	cop	_	_
32	not	not	RB	RB	_	33	neg	_	_
33	present	present	JJ	JJ	_	0	root	_	_
34	in	in	IN	IN	_	37	case	_	_
35	peripheral	peripheral	JJ	JJ	_	37	amod	_	_
36	T	t	NN	NN	_	37	compound	_	_
37	cells	cell	NNS	NNS	_	33	nmod	_	_
38	.	.	.	.	_	33	punct	_	_

1	Consequently	consequently	RB	RB	_	11	advmod	_	_
2	,	,	,	,	_	11	punct	_	_
3	T	t	NN	NN	_	4	compound	_	_
4	lymphocytes	lymphocyte	NNS	NNS	_	11	nsubjpass	_	_
5	present	present	JJ	JJ	_	4	amod	_	_
6	in	in	IN	IN	_	8	case	_	_
7	the	the	DT	DT	_	8	det	_	_
8	spleen	spleen	NN	NN	_	5	nmod	_	_
9	can	can	MD	MD	_	11	aux	_	_
10	be	be	VB	VB	_	11	auxpass	_	_
11	activated	activate	VBN	VBN	_	0	root	_	_
12	normally	normally	RB	RB	_	11	advmod	_	_
13	in	in	IN	IN	_	14	case	_	_
14	response	response	NN	NN	_	11	nmod	_	_
15	to	to	TO	TO	_	17	case	_	_
16	either	either	DT	DT	_	17	det	_	_
17	stimulus	stimulus	NN	NN	_	14	nmod	_	_
18	mentioned	mention	VBN	VBN	_	17	acl	_	_
19	above	above	RB	RB	_	18	advmod	_	_
20	,	,	,	,	_	11	punct	_	_
21	demonstrating	demonstrate	VBG	VBG	_	11	advcl	_	_
22	that	that	IN	IN	_	32	mark	_	_
23	the	the	DT	DT	_	24	det	_	_
24	effects	effect	NNS	NNS	_	32	nsubj	_	_
25	of	of	IN	IN	_	28	case	_	_
26	the	the	DT	DT	_	28	det	_	_
27	inactive	inactive	JJ	JJ	_	28	amod	_	_
28	CaMKIV	camkiv	NN	NN	_	24	nmod	_	_
29	on	on	IN	IN	_	30	case	_	_
30	activation	activation	NN	NN	_	24	nmod	_	_
31	are	be	VBP	VBP	_	32	cop	_	_
32	reversible	reversible	JJ	JJ	_	21	ccomp	_	_
33	.	.	.	.	_	11	punct	_	_

1	Our	we	PRP$	PRP$	_	2	nmod:poss	_	_
2	results	result	NNS	NNS	_	3	nsubj	_	_
3	suggest	suggest	VBP	VBP	_	0	root	_	_
4	that	that	IN	IN	_	7	mark	_	_
5	CaMKIV	camkiv	NN	NN	_	7	nsubj	_	_
6	may	may	MD	MD	_	7	aux	_	_
7	represent	represent	VB	VB	_	3	ccomp	_	_
8	a	a	DT	DT	_	12	det	_	_
9	physiologically	physiologically	RB	RB	_	10	advmod	_	_
10	relevant	relevant	JJ	JJ	_	12	amod	_	_
11	CREB	creb	NN	NN	_	12	compound	_	_
12	kinase	kinase	NN	NN	_	7	dobj	_	_
13	in	in	IN	IN	_	15	case	_	_
14	T	t	NN	NN	_	15	compound	_	_
15	cells	cell	NNS	NNS	_	7	nmod	_	_
16	and	and	CC	CC	_	7	cc	_	_
17	that	that	IN	IN	_	22	mark	_	_
18	the	the	DT	DT	_	19	det	_	_
19	enzyme	enzyme	NN	NN	_	22	nsubjpass	_	_
20	is	be	VBZ	VBZ	_	22	auxpass	_	_
21	also	also	RB	RB	_	22	advmod	_	_
22	required	require	VBN	VBN	_	7	conj	_	_
23	to	to	TO	TO	_	24	mark	_	_
24	ensure	ensure	VB	VB	_	22	xcomp	_	_
25	normal	normal	JJ	JJ	_	26	amod	_	_
26	expansion	expansion	NN	NN	_	24	dobj	_	_
27	of	of	IN	IN	_	29	case	_	_
28	T	t	NN	NN	_	29	compound	_	_
29	cells	cell	NNS	NNS	_	26	nmod	_	_
30	in	in	IN	IN	_	32	case	_	_
31	the	the	DT	DT	_	32	det	_	_
32	thymus	thymus	NN	NN	_	26	nmod	_	_
33	.	.	.	.	_	3	punct	_	_

1	Whereas	whereas	IN	IN	_	9	mark	_	_
2	the	the	DT	DT	_	3	det	_	_
3	pathway	pathway	NN	NN	_	9	nsubj	_	_
4	responsible	responsible	JJ	JJ	_	3	amod	_	_
5	for	for	IN	IN	_	8	case	_	_
6	this	this	DT	DT	_	8	det	_	_
7	latter	latter	JJ	JJ	_	8	amod	_	_
8	role	role	NN	NN	_	4	nmod	_	_
9	is	be	VBZ	VBZ	_	17	advcl	_	_
10	yet	yet	RB	RB	_	9	advmod	_	_
11	to	to	TO	TO	_	13	mark	_	_
12	be	be	VB	VB	_	13	auxpass	_	_
13	elucidated	elucidate	VBN	VBN	_	9	xcomp	_	_
14	,	,	,	,	_	17	punct	_	_
15	it	it	PRP	PRP	_	17	nsubj	_	_
16	is	be	VBZ	VBZ	_	17	cop	_	_
17	unlikely	unlikely	JJ	JJ	_	0	root	_	_
18	to	to	TO	TO	_	19	mark	_	_
19	include	include	VB	VB	_	17	xcomp	_	_
20	CREB	creb	NN	NN	_	21	compound	_	_
21	phosphorylation	phosphorylation	NN	NN	_	19	dobj	_	_
22	.	.	.	.	_	17	punct	_	_

